MX2022003982A - Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1. - Google Patents

Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1.

Info

Publication number
MX2022003982A
MX2022003982A MX2022003982A MX2022003982A MX2022003982A MX 2022003982 A MX2022003982 A MX 2022003982A MX 2022003982 A MX2022003982 A MX 2022003982A MX 2022003982 A MX2022003982 A MX 2022003982A MX 2022003982 A MX2022003982 A MX 2022003982A
Authority
MX
Mexico
Prior art keywords
sub
methods
receptor
conditions related
treating conditions
Prior art date
Application number
MX2022003982A
Other languages
English (en)
Inventor
Thai Curtis Nguyen-Cleary
Lisette Marie Acevedo
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MX2022003982A publication Critical patent/MX2022003982A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)

Abstract

Se proporcionan métodos de tratamiento de enfermedad de Crohn que comprenden prescribir y/o administrar a un individuo en necesidad de lo mismo una dosis estándar de ácido (R)-2-(7-(4-ciclopentil-3- (trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3 -il)acético (Compuesto 1), o una sal, hidrato o solvato farmacéuticamente aceptable del mismo.
MX2022003982A 2019-10-01 2020-09-30 Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1. MX2022003982A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962909113P 2019-10-01 2019-10-01
PCT/US2020/053642 WO2021067506A1 (en) 2019-10-01 2020-09-30 Methods of treating conditions related to the s1p1 receptor

Publications (1)

Publication Number Publication Date
MX2022003982A true MX2022003982A (es) 2022-07-12

Family

ID=75337529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003982A MX2022003982A (es) 2019-10-01 2020-09-30 Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1.

Country Status (12)

Country Link
US (1) US20220347158A1 (es)
EP (1) EP4037678A4 (es)
JP (1) JP2022550458A (es)
KR (1) KR20220074913A (es)
CN (1) CN115038438A (es)
AU (1) AU2020360413A1 (es)
BR (1) BR112022005999A2 (es)
CA (1) CA3156182A1 (es)
IL (1) IL291654A (es)
MX (1) MX2022003982A (es)
TW (1) TW202114656A (es)
WO (1) WO2021067506A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118541151A (zh) 2022-01-13 2024-08-23 艾尼纳制药公司 与激素治疗组合的用于治疗s1p1受体相关病症的伊曲莫德

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180023049A (ko) * 2008-07-23 2018-03-06 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
WO2011094008A1 (en) * 2010-01-27 2011-08-04 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
EP4445956A2 (en) * 2015-01-06 2024-10-16 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
MA47503A (fr) * 2017-02-16 2021-04-21 Arena Pharm Inc Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales

Also Published As

Publication number Publication date
CN115038438A (zh) 2022-09-09
AU2020360413A1 (en) 2022-04-14
EP4037678A1 (en) 2022-08-10
JP2022550458A (ja) 2022-12-01
KR20220074913A (ko) 2022-06-03
US20220347158A1 (en) 2022-11-03
AU2020360413A8 (en) 2022-04-21
BR112022005999A2 (pt) 2022-07-12
IL291654A (en) 2022-05-01
EP4037678A4 (en) 2023-11-29
CA3156182A1 (en) 2021-04-08
TW202114656A (zh) 2021-04-16
WO2021067506A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
MX2020013157A (es) Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
NZ771435A (en) Methods of treating conditions related to the s1p1 receptor
WO2005046318A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
MX2022008342A (es) Metodos para tratar afecciones relacionadas con el receptor de s1p1.
MX2021008263A (es) Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
MX2023001468A (es) Tratamiento de cancer de prostata.
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
WO2005044178A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX2019009841A (es) Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
EA202191079A1 (ru) Способы лечения синдрома ретта с применением фенфлурамина
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2021009909A (es) Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.
RU2018134167A (ru) Комбинированная терапия для лечения острого миелоидного лейкоза
PH12019502651A1 (en) Use of vibegron to treat overactive bladder
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
MX2022006083A (es) Metodos para tratar afecciones relacionadas con el receptor s1p1.
JP2014512355A5 (es)
MX2020011453A (es) Combinaciones para tratar el cancer.
MX2021003842A (es) Terapia combinada para el tratamiento del cancer.
JP6247004B2 (ja) 帯状疱疹関連通の急性期疼痛の予防又は治療剤
RU2020120156A (ru) Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена
MX2022003982A (es) Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1.